CD8A and malaria: Most candidate vaccines in clinical development are based on the classical vaccination approach of a single vaccine administered in a homologous prime–boost schedule which induce primarily neutralizing antibodies but weak CD4+ and no CD8+ T-cells.6 This approach may account for the inadequate protection generated by the candidate vaccines, and justifies the need for other approaches to induce and sustain strong T-cell responses and help alleviate the huge mortality associated with malaria.